AVCRF Avricore Health Inc. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1355736 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY33.7%
TTM net income YoY4.6%
TTM EPS YoY0.0%
Revenue 3-yr CAGR236.0%
Net income 3-yr CAGR—
Margins
Gross margin40.4%
Operating margin—
Net margin-14.4%
FCF margin17.7%
EBITDA margin—
Returns
ROE-33.6%
ROA-27.7%
ROIC (approx.)—
Asset turnover1.93x
Leverage & solvency
Liabilities / assets14.4%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.50x
Accruals ratio-69.2%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 4.66M | 3.48M | 1.77M | 122,808 | 33,030 |
| Cost of revenue | 2.91M | 2.28M | 1.31M | 92,287 | 15,550 |
| Gross profit | 1.88M | 1.20M | 456,793 | 30,521 | 17,480 |
| SG&A expense | 409,398 | 339,369 | 250,144 | 182,847 | 114,227 |
| Interest expense | — | — | — | 38,438 | 158,952 |
| Pretax income | 129,001 | -693,253 | -817,945 | -1.75M | — |
| Net income | -668,977 | -701,215 | -818,228 | -1.71M | -1.17M |
| EPS (basic) | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | -0.02 | — |
| Weighted avg. shares (diluted) | 100.31M | 99.56M | 97.86M | — | — |
| Balance sheet | |||||
| Cash & equivalents | 1.13M | 276,571 | 620,527 | 2.01M | 302,715 |
| Receivables | 419,587 | 427,689 | 770,373 | 91,548 | 11,928 |
| Inventory | 507 | 20,676 | — | — | — |
| Current assets | 1.58M | 773,561 | 1.43M | 2.16M | 440,087 |
| PP&E, netmay include right-of-use assets (IFRS) | 656,441 | 1.72M | 1.11M | 90,875 | 0 |
| Intangibles | — | — | 29,861 | — | — |
| Total assets | 2.30M | 2.54M | 2.57M | 2.28M | 440,090 |
| Current liabilities | — | — | 604,893 | — | — |
| Total liabilities | 330,817 | 529,218 | 604,893 | 84,477 | 1.15M |
| Shareholders' equity | 1.97M | 2.01M | 1.96M | 2.20M | -724,041 |
| Cash flow statement | |||||
| Operating cash flow | 1.00M | 660,403 | -437,832 | -1.23M | -1.22M |
| Capital expenditure | 181,094 | 1.02M | 1.19M | 105,358 | — |
| Free cash flow | 823,521 | -361,168 | -1.63M | -1.34M | — |
| Investing cash flow | -205,347 | -1.05M | -1.21M | -140,364 | 0 |
| Financing cash flow | 56,600 | 42,500 | 253,880 | 3.08M | 1.51M |
| Depreciation & amortization | 3,137 | 2,347 | 631 | 17,984 | 0 |
| Stock-based compensation | 541,164 | 703,612 | 331,522 | 495,791 | 130,219 |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.